Condition
KRAS G12C Mutant Advanced Solid Tumors
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Fulzerasib Cetuximab N01
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 1/2 (1)
Phase 2 (1)
Trial Status
Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07581912Phase 2Recruiting
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
NCT06237400Phase 1/2UnknownPrimary
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Showing all 2 trials
Research Network
Common Treatments
- Fulzerasib Cetuximab N011
- Zg190181
Active Sponsors
- Zhejiang University1
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd1
Top Investigators
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Second Affiliated Hospital, Zhejiang University, School of Medicine
Related Conditions
- Fulzerasib1
- Cetuximab N011
- Colorectal Cancer1